MAGENTA THERAPEUTICS ANNOUNCES DATA PRESENTATIONS RELATED TO ITS MOBILIZATION AND CONDITIONING PROGRAMS AT THE 2021 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
— Positive topline clinical data from MGTA-145 investigator-initiated Phase 2 clinical trial in multiple myeloma —
— Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle cell disease —
— Successful conditioning with CD117 antibody drug conjugate in combination with lymphodepleting antibodies leading to effective allogeneic hematopoietic stem cell transplant in a murine model of acute myeloid leukemia —
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2021– Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced positive top-line results from an investigator-initiated Phase 2 clinical trial of MGTA-145 stem cell mobilization in multiple myeloma. The data were accepted for a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, to be held in Atlanta and virtually from December 11-14, 2021. Oral and poster presentations of preclinical data related to the company’s CD117 targeted conditioning program will also be made at the ASH Annual Meeting.
“We have made significant progress with our mobilization and targeted conditioning programs and we look forward to the presentation of the data that have been generated to support both programs,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics.
Stem Cell Mobilization and Collection Program (MGTA-145)
Poster Presentation Highlighting Investigator-Initiated Phase 2 Clinical Data of MGTA-145 Stem Cell Mobilization in Multiple Myeloma:
Title: MGTA-145 + Plerixafor Provides G-CSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study (Poster #3888)
Date and Time to View Poster Presentation: Monday, December 13, 2021, 6:00pm – 8:00pm ET
Surbhi Sidana, M.D., Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University School of Medicine led this investigator-initiated, Phase 2 open-label clinical trial. The trial evaluated the ability of MGTA-145, in combination with plerixafor, to mobilize stem cells for autologous stem cell transplantation in patients with multiple myeloma. This trial had broad inclusion criteria and included the transplant-eligible population of patients with multiple myeloma who may have a variety of risk factors for mobilization.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?